Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Towards a combinatorial approach for the prediction of immunoglobulin G half-life and clearance.

Goulet DR, Watson MJ, Tam SH, Zwolak A, Chiu ML, Atkins WM, Nath A.

Drug Metab Dispos. 2018 Sep 19. pii: dmd.118.081893. doi: 10.1124/dmd.118.081893. [Epub ahead of print]

PMID:
30232177
2.

Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer.

Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM.

Oncotarget. 2018 Jan 29;9(21):15480-15497. doi: 10.18632/oncotarget.24337. eCollection 2018 Mar 20.

3.

Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies.

Goulet DR, Orcutt SJ, Zwolak A, Rispens T, Labrijn AF, de Jong RN, Atkins WM, Chiu ML.

J Biol Chem. 2018 Jan 12;293(2):651-661. doi: 10.1074/jbc.RA117.000303. Epub 2017 Nov 17.

4.

Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding.

Zwolak A, Leettola CN, Tam SH, Goulet DR, Derebe MG, Pardinas JR, Zheng S, Decker R, Emmell E, Chiu ML.

Sci Rep. 2017 Nov 14;7(1):15521. doi: 10.1038/s41598-017-15748-0.

5.

Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding.

Zwolak A, Armstrong AA, Tam SH, Pardinas JR, Goulet DR, Zheng S, Brosnan K, Emmell E, Luo J, Gilliland GL, Chiu ML.

MAbs. 2017 Nov/Dec;9(8):1306-1316. doi: 10.1080/19420862.2017.1375639. Epub 2017 Sep 12.

6.

Diffusion of Soluble Aggregates of THIOMABs and Bispecific Antibodies in Serum.

Goulet DR, Zwolak A, Chiu ML, Nath A, Atkins WM.

Biochemistry. 2017 May 2;56(17):2251-2260. doi: 10.1021/acs.biochem.6b01097. Epub 2017 Apr 14.

7.

Landscaping a chromatin response to MEK inhibition.

Zawistowski JS, Goulet DR, Johnson GL.

Cell Cycle. 2017 Apr 18;16(8):731-732. doi: 10.1080/15384101.2017.1302232. Epub 2017 Mar 13. No abstract available.

8.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.

9.

Targeting the Breast Cancer Kinome.

Miller SM, Goulet DR, Johnson GL.

J Cell Physiol. 2017 Jan;232(1):53-60. doi: 10.1002/jcp.25427. Epub 2016 May 31. Review.

PMID:
27186656
10.

Inhibition of unfolding and aggregation of lens protein human gamma D crystallin by sodium citrate.

Goulet DR, Knee KM, King JA.

Exp Eye Res. 2011 Oct;93(4):371-81. doi: 10.1016/j.exer.2011.04.011. Epub 2011 May 12.

11.

The group II chaperonin Mm-Cpn binds and refolds human γD crystallin.

Knee KM, Goulet DR, Zhang J, Chen B, Chiu W, King JA.

Protein Sci. 2011 Jan;20(1):30-41. doi: 10.1002/pro.531.

12.

Crystal structures of a group II chaperonin reveal the open and closed states associated with the protein folding cycle.

Pereira JH, Ralston CY, Douglas NR, Meyer D, Knee KM, Goulet DR, King JA, Frydman J, Adams PD.

J Biol Chem. 2010 Sep 3;285(36):27958-66. doi: 10.1074/jbc.M110.125344. Epub 2010 Jun 23.

Supplemental Content

Loading ...
Support Center